ライフサイエンスコーパス: pretransfusion

1 Pretransfusion and final hematocrits were similar (P > 0

2 89 subjects were tested for GBV-C markers in pretransfusion and posttransfusion samples.

3 nto a population of surgical patients with a pretransfusion B19V IgG seroprevalence of 78%.

4 ch as bedside handheld scanners to carry out pretransfusion bedside checking.

5 laboratory characteristics of children with pretransfusion cerebral tSo2 levels less than 65%, 65% t

6 alyses of the laboratory methods used during pretransfusion compatibility testing in the United State

7 The purpose of pretransfusion compatibility testing is to prevent incom

8 iterature to present the current practice of pretransfusion compatibility testing.

9 ion hazard periods was compared with that in pretransfusion control periods, stratifying the risk bas

10 Number of transfusions with mean pretransfusion Csat less than 50% was associated with ND

11 Lower pretransfusion Csat may be associated with adverse outco

12 sions indicated for threshold were given for pretransfusion Hb levels above restrictive transfusion t

13 Mean (SD) pretransfusion HB of transfused LLDs was 11.7 g/dL (+/-1

14 ce rates, cumulative incidence, indications, pretransfusion hemoglobin (Hb) levels, volumes, and tran

15 ICU were independently associated with lower pretransfusion hemoglobin concentrations.

16 L vs. 9.3 +/- 1.41 g/dL, p = .02) as was the pretransfusion hemoglobin level (8.0 +/- 0.5 g/dL vs. 7.

17 tion, recipient age and body mass index, and pretransfusion hemoglobin levels were significant predic

18 The pretransfusion hemoglobin observed in our study was lowe

19 Forty children were included; mean pretransfusion hemoglobin S concentration was 29%.

20 The mean pretransfusion hemoglobin was 8.6 +/- 1.7 g/dL.

21 Although men and women had similar pretransfusion hemoglobin, men had significantly increas

22 95% confidence interval 0.1-1.1 g/dL) higher pretransfusion hemoglobin.

23 Pretransfusion hepcidin was positively correlated with h

24 on of an adenosine-5'-triphosphate analog or pretransfusion incubation of the red blood cells with an

25 ring their intensive care unit stay, but the pretransfusion international normalized ratio value vari

26 fants, birth weight 865 ( 375) g, had higher pretransfusion KIM-1 levels of 2270 (830, 3250) pg/mg th

27 els peaked to 3300 pg/mg; levels returned to pretransfusion levels of 2240 (1240, 3870) pg/mg by 24 h

28 ost-transfusion KIM-1 levels were similar to pretransfusion levels, p = 0.63.

29 and 28 days after transfusion, compared with pretransfusion levels.

30 1.9 g per deciliter (19 g per liter) in the pretransfusion mean hemoglobin levels throughout the tre

31 Pretransfusion patient characteristics were naturally di

32 The pretransfusion PCT was at least 50000/muL for 653 of 998

33 s were categorized as hazard periods and the pretransfusion periods of variable duration as control p

34 rare P-deficient P1 (k) phenotype and whose pretransfusion plasma was unexpectedly incompatible with

35 Pretransfusion platelet counts (11 x 10(9)/L) were simil

36 anomalies by including multiple testing of a pretransfusion sample that acts as a specificity control

37 and blood samples from all blood donors, and pretransfusion samples were collected from all recipient

38 ty than controls (P <.05), and compared with pretransfusion samples, TRALI patients' plasma demonstra

39 human leukocyte antigen antibody may permit pretransfusion screening of selected patients and provid

40 We found an anamnestic IgG response in one pretransfusion seropositive recipient transfused with a

41 nt of all conventional serologic methods for pretransfusion testing by molecular methods is not strai

42 lonal antibody therapies that interfere with pretransfusion testing.

43 All donor blood samples must be tested pretransfusion to determine the donor blood type.

44 uce the number of HLA-bearing leukocytes, or pretransfusion ultraviolet B irradiation of cellular com